# The Use of Reference Priors and Bayes Factors in the Analysis of Clinical Trials

## Abstract

This paper was motivated by foundational issues that underlie the application of Bayesian methods. Advances in numerical methods and computation make applying Bayesian methods relatively easy, so now as a discipline we can step back and contemplate what these new tools will allow us to do with respect to the theoretical foundations of our work, and if desired, adjust our actions accordingly. The foundational issues that this paper will address are the use of reference priors and the use of Bayes factors in the analysis of clinical trials. The question that merges these two foundational issues is “Should data analysis and decision-making be approached as two separate tasks or should there be a seamless integration with each stage of the clinical trial being viewed as a subsequent step in a sequential decision-making problem?”

### Keywords

Pneumonia Heparin Coherence Plasminogen Streptokinase## Preview

Unable to display preview. Download preview PDF.

### References

- [1]Berger J.O.,
*Robust Bayesian analysis: sensitivity to the prior*, Journal of Statistical Planning and Inference, 25, 1990, pp. 303–328.MathSciNetMATHCrossRefGoogle Scholar - [2]Berry D.A.,
*Interim analysis in clinical trials: classical versus Bayesian approaches*, Statistics in Medicine, 4, 1985, pp. 521–526.CrossRefGoogle Scholar - [3]Berry, D.A.,
*Interim analysis in clinical trials: The role of the likelihood principle*, The American Statistician, 41, 1987, pp. 117–122.MathSciNetMATHGoogle Scholar - [4]Berry, D.A.,
*Interim analysis in clinical research*, Cancer Invest., 5, (1988a), pp. 469–477.CrossRefGoogle Scholar - [5]Berry, C.A.,
*Multiple comparisons, multiple tests, and data dredging: A Bayesian perspective with discussion)*. In*Bayesian Statistics 3*, (eds. J.M. Bernardo, M.H. DeGroot, D.V. Lindley, and A.F.M. Smith), Oxford University Press, (1988b), pp. 79–94.Google Scholar - [6]Berry, D.A.,
*Monitoring accumulating data in a clinical trial*, Biometrics, 45, 1989a, pp. 1197–1211.MathSciNetMATHCrossRefGoogle Scholar - [7]Berry, D.A.,
*Inferential aspects of adaptive allocation rules*, Proceedings of the Pharmaceutical Section of the American Statistical Association, ASA, Washington DC, 1989c, pp. 1–8.Google Scholar - [8]Berry D.A.,
*Bayesian methodology in phase III trials*, Drug Information Association Journal, 25, 1991, pp. 345–368.CrossRefGoogle Scholar - [9]Berry DA,
*Experimental design for drug development: A Bayesian approach*, Journal of Biopharmaceutical Statistics, 1, 1991, pp. 81–101.MATHCrossRefGoogle Scholar - [10]Berry, D.A.,
*A case for Bayesianism in clinical trials (with discussion)*, Statistics in Medicine, 12, 1993, pp. 1377–1404.CrossRefGoogle Scholar - [11]Berry, D.A.,
*Decision analysis and Bayesian methods in clinical trials*, In*Recent Advances in Clinical Trial Design and Analysis*, (ed. P. Thall), Kluwer Press, New York, 1995, pp. 125–154.CrossRefGoogle Scholar - [12]Berry D.A., and Fristedt, B.,
*Bandit Problems: Sequential Allocation of Experiments*, London: Chapman-Hall, 1985.MATHGoogle Scholar - [13]Berry, D.A., and Hardwick, J.,
*Using historical controls in clinical trials: Application to ECMO*, Statistical Decision Theory and Related Topics V, New York: Springer-Verlag, (eds. Berger JO, Gupta S), 1993, pp. 141–156.Google Scholar - [14]Berry, D.A., and Eick, S.G.,
*Adaptive assignment versus balanced randomization in clinical trials: A decision analysis*, Statistics in Medicine, 14, 1994, pp. 231–246.Google Scholar - [15]Berry, D.A., and Ho, C.H.,
*One-sided sequential stopping boundaries for clinical trials: A decision-theoretic approach*, Biometrics, 44, 1988, pp. 219–227.MathSciNetMATHCrossRefGoogle Scholar - [16]Berry, D.A., Wolff, M.C., and Sack, D.,
*Public health decision making: A sequential vaccine trial (with discussion)*, In*Bayesian Statistics*, (eds. Bernardo JM, Berger JO, Dawid AP, Smith AFM), Oxford, England: Oxford University Press, 1992, pp. 79–96.Google Scholar - [17]Berry, D.A., Wolff, M.C., and Sack, D.,
*Decision making during a phase III randomized controlled trial*, Controlled Clinical Trials, 15, 1994, pp. 360–379.CrossRefGoogle Scholar - [18]Breslow, N.,
*Biostatistics and Bayes*, Statistical Science, 5, 1990, pp. 269–284.MathSciNetMATHCrossRefGoogle Scholar - [19]Brophy J.M., and Joseph, L.,
*Placing trials in context using Bayesian analysis: Gusto revisited by Reverend Bayes*, Journal of the American Medical Association, 273(11), 1995, pp. 871–875.CrossRefGoogle Scholar - [20]Carlin, B.P., and Louis, T.A.,
*Bayes and Empirical Bayes Methods for Data Analysis*, Chapman and Hall, 1996.Google Scholar - [21]Carlin, B.P., Chaloner, K. M., Louis, T.A., and Rhame, F.S.,
*Elicitation, monitoring, and analysis for an AIDS clinical trial*, In*Case Studies in Bayesian Statistics: Volume II*, (eds. C. Gatsonis, J. Hodges, R. Kass, and N. Singpur-walla), Springer, 1995, pp. 48–84.Google Scholar - [22]Chaloner, K.,
*Elicitation of Prior Distributions*, In*Bayesian Biostatistics*, (eds. D.A. Berry and D.K. Stangl), Marcel Dekker, 1996, pp. 141–156.Google Scholar - [23]Chaloner, K., Church, T., Matts, J.P., and Louis, T.A.,
*Graphical elicitation of a prior distribution for an AIDS clinical trial*, The Statistician, 42, 1993, pp. 341–353.CrossRefGoogle Scholar - [24]Craig, P.S., Goldstein, M., Seheult, A.H., and Smith, J.A.,
*Constructing partial prior specifications for models of complex physical systems*, The Statistician, 47(1), 1998, pp. 37–53.Google Scholar - [25]Gail, M.,
*A discussion of: Bayesian approaches to randomized trials*, J. Royal Statistical Soc. Ser. A, 157, 1995, pp. 357–416.Google Scholar - [26]Gelman, A., Carlin, J.B., Stern, H.S., and Rubin, D. B.,
*Bayesian Data Analysis*, Chapman & Hall, London, 1995.Google Scholar - [27]Greenhouse J.B., and Wasserman, L.,
*A practical, robust method for Bayesian model selection:*A case*study in the analysis of clinical trials*, Paper presented at the American Statistical Association Meetings, Carnegie-Mellon Technical Report #626, 1995a.Google Scholar - [28]Greenhouse, J.B., and Wasserman, L.,
*Robust Bayesian methods for monitoring clinical trials*, Statistics in Medicine, 14, 1995b, pp. 1379–1391.CrossRefGoogle Scholar - [29]Greenhouse, J.B.,
*On some applications of Bayesian methods in cancer clinical trials*, Statistics in Medicine, 11, 1992, pp. 37–53.Google Scholar - [30]Hilden, J. and Habbema, J.,
*The marriage of clinical trials and clinical decision science*, Statistics in Medicine, 9, 1990, pp. 1243–1257.CrossRefGoogle Scholar - [31]Hively, W.,
*The mathematics of making up your mind*, Discover, May 1996.Google Scholar - [32]Kadane, J.B., and Wolfson, L. J.,
*Priors for the design and analysis of clinical trials*, In*Bayesian Biostatistics*, D. Berry and D. Stangl (eds.), Marcel Dekker, New York 1996.Google Scholar - [33]Kadane, J.B., and Wolfson, L. J.,
*Experiences in elicitation*, The Statistician, 47(1), 1998, pp. 3–19.Google Scholar - [34]Kadane, J.B., and Dickey, J.M.,
*Bayesian decision theory and the simplification of models*, In*Evaluation of Econometric Models*, (eds. J. Kmenta and J. Ramsey), Academic Press, 1980, pp. 245–268.Google Scholar - [35]Lavine, M., and Schervish, M.,
*Bayes factors: What they are and what they are not*, The Statistician, 1999, to appear.Google Scholar - [36]Lindley, D.,
*A discussion of: Bayesian approaches to randomized trials*, J. Royal Statistical Soc. Ser. A, 157, 1995, pp. 357–416Google Scholar - [37]O’Hagan, A.,
*Eliciting expert beliefs in substantial practical applications*, The Statistician, 47(1), 1998, pp. 21–35.MathSciNetGoogle Scholar - [38]Parmigiani, G., Ancukiewicz, M. and Matchar, D.,
*Decision models in clinical recommendations development: The stroke prevention policy model*, In*Bayesian Biostatistics*, ed. D.A. Berry and D.K. Stangl, Marcel Dekker, 1996, pp. 207–233.Google Scholar - [39]Parmigiani, G. and Kamlet, M.S.,
*A cost-utility analysis of alternative strategies in screening for breast cancer*, In*Case Studies in Bayesian Statistics*, (eds. C. Gatsonis, J. Hodges, R. Kass, and N. Singpurwalla, Springer-Verlag, 1993, pp. 390–402.Google Scholar - [40]Sargent, D. and Carlin, B.P.,
*Robust Bayesian design and analysis of clinical trials via prior partitioning (with discussion)*, IMS Lecture Note Series: Second International Workshop on Bayesian Robustness, 1996.Google Scholar - [41]Simes, R.J.,
*Application of statistical decision theory to treatment choices: Implications for the design and analysis of clinical trials*, Statistics in Medicine, 5, 1986, pp. 411–420.CrossRefGoogle Scholar - [42]Spiegelhalter, D.J., Freedman, L.S., and Parmar, M.K.,
*Bayesian approaches to randomized trials*, J. Royal Statistical Soc. Ser. A, 157, 1994, pp. 357–416.MathSciNetMATHCrossRefGoogle Scholar - [43]Stangl, D.,
*Prediction and decision making using Bayesian hierarchical models*, Statistics in Medicine, 14, 1995, pp. 2173–2190.CrossRefGoogle Scholar - [44]The Gusto Investigators,
*An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction*, N. Engl. J. Med., 329, 1993, pp. 673–682.CrossRefGoogle Scholar - [45]Wasserman, L.,
*Recent methodological advances in robust Bayesian inference*, In*Bayesian Statistics IV*, (eds. J.M. Bernardo, M.H. DeGroot, D.V. Lindley, and A.F.M. Smith), Oxford University Press, 1992, pp. 483–502.Google Scholar